Inex Marqibo Phase III Preparation Includes Company Restructuring

The company will reduce its workforce from 165 to 62 employees, including executive-level resignations. Inex plans a Phase III comparative trial of the liposomal vincristine product in first- or second-line non-Hodgkin’s lymphoma or acute lymphoblastic leukemia following a negative advisory committee review for third-line NHL.